Further, platelet-derived GPIbα was found to be a critical mediator and potential interventional target for the development of MASH and subsequent liver cancer, and antiplatelet therapy (aspirin/clopidogrel, and ticagrelor) may prevent the development of MASH and subsequent liver cancer through suppression of intrahepatic platelet accumulation and cytokine and chemokine release (Malehmir et al., 2019). Here, GP1BA is linked to liver cancer.